** Ireland-based commercial stage biotechnology company Trinity Biotech's TRIB.O shares rise 8.7% to $0.73 premarket
** Co says it will strengthen focus on its Continuous Glucose Monitoring (CGM) technology
** Says that the successful execution of its comprehensive transformation plan is expected to drive near-term profitability improvements
** Co also appoints Barclays as its exclusive financial advisor to support strategic realignment
** Up to Wednesday's close, stock had fallen 22.7% so far this year
(Reporting by Anushka Chourasia)
((Anushka.Chourasia@thomsonreuters.com;))